Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24650853 | 1.00 | EGFR (0.45) | EGFRF2HTTHSD17B10MTNR1A | |
| Hydrochloric Acid SCHEMBL4151104 | 0.99 | EGFR (0.44) | EGFRF2HTTHSD17B10 | |
| SCHEMBL24650854 | 0.86 | F2 (0.43) | EGFRF2MTNR1AMTNR1BNOTUM | |
| SCHEMBL3315502 | 0.86 | CYP1A2 (0.45) | HSD17B10MEN1CYP1A2TSHRMAPK1 | |
| SCHEMBL24650861 | 0.83 | F2 (0.47) | F2MTNR1AMTNR1BNOTUM | |
| SCHEMBL24650859 | 0.82 | F2 (0.51) | F2NOTUM | |
| SCHEMBL24650907 | 0.82 | SHBG (0.42) | EGFR | |
| SCHEMBL24650903 | 0.82 | MIF (0.40) | MTNR1AMTNR1B | |
| SCHEMBL24650858 | 0.81 | PYGL (0.42) | EGFR | |
| SCHEMBL10734798 | 0.81 | HDAC4 (0.47) | EGFRMTNR1AMTNR1BNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137397-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | US | disclosed |
| US-20100137397-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | US | disclosed |
| US-20090124682-A1 | Indan-Amide Derivatives with Glycogen Phosphorylase Inhibitory Activity | BIRCH ALAN MARTIN | 2009-05-14 | — | — | US | disclosed |
| US-20090124682-A1 | Indan-Amide Derivatives with Glycogen Phosphorylase Inhibitory Activity | BIRCH ALAN MARTIN | 2009-05-14 | — | — | US | disclosed |
| US-20090124682-A1 | Indan-Amide Derivatives with Glycogen Phosphorylase Inhibitory Activity | BIRCH ALAN MARTIN | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137397-A1 | Chemical Compounds | PYGL, PYGM, GYS2 | EGFR 4015/4885F2 2727/4885HTT 2060/4885 |
| US-20090124682-A1 | Indan-Amide Derivatives with Glycogen Phosphorylase Inhibitory Activity | PYGL, PYGM, GYS1 | EGFR 2948/4885F2 4461/4885HTT 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.